These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 22517614)
1. Rationale for cholesteryl ester transfer protein inhibition. Hewing B; Fisher EA Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614 [TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Mohammadpour AH; Akhlaghi F Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137 [TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Shinkai H Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899 [TBL] [Abstract][Full Text] [Related]
4. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288 [TBL] [Abstract][Full Text] [Related]
6. Dalcetrapib: a review of Phase II data. Robinson JG Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364 [TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?]. Murín J; Pernický M; Kiňová S Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865 [TBL] [Abstract][Full Text] [Related]
9. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191 [TBL] [Abstract][Full Text] [Related]
10. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Niesor EJ Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074 [TBL] [Abstract][Full Text] [Related]
11. The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. Bochem AE; Kuivenhoven JA; Stroes ES Curr Pharm Des; 2013; 19(17):3143-9. PubMed ID: 23317399 [TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Filippatos TD; Klouras E; Barkas F; Elisaf M Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534 [TBL] [Abstract][Full Text] [Related]
13. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069 [TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Mabuchi H; Nohara A; Inazu A Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012 [TBL] [Abstract][Full Text] [Related]
16. The end of the road for CETP inhibitors after torcetrapib? Joy T; Hegele RA Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058 [TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613 [TBL] [Abstract][Full Text] [Related]
20. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]